Beheer

The next publication of Horizonscan Geneesmiddelen is planned for {0}. Please enter information for new or existing medicines before {0}.

Recent

Portfolio

Alvleesklierkanker

Ocrelizumab

Status

Published
Tocilizumab

Status

Published

Huidkanker

Vemurafenib
Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab

Status

Published
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

Status

Published

Longkanker

Alectinib

Status

Change request
Atezolizumab
Treatment (monotherapy) of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving atezolizumab

Status

Published
NSCLC, 2e behandeling

Status

Published

Blaaskanker

Atezolizumab

Status

Published

Lymfeklierkanker

Obinutuzumab

Status

Published

Borstkanker

Atezolizumab
Indication couldn't be found

Status

Published
Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Status

Published
Pertuzumab

Status

Published

Maagkanker

Pertuzumab

Status

Change request

Navragen bij deskundigen

Max Meijer

Nivolumab

Ter beoordeling

De volgende documenten zijn bewerkt door Zorginstituut Nederland en kunnen door u nagekeken worden.

Vemurafenib

Wijzigingsverzoeken

Er zijn op dit moment geen wijzingsverzoeken van u in behandeling.

Nieuwe geneesmiddelen

U heeft de volgende nieuwe records voorgesteld voor de volgende publicatie van Horizonscan Geneesmiddelen.

coronine

New record

Understanding of expected market entry
of innovative medicines

Recent

Ipilimumab

Portfolio

Alvleesklierkanker

Ocrelizumab

Status

Tocilizumab

Status

Huidkanker

Vemurafenib

Status

Status

Longkanker

Alectinib

Status

Atezolizumab

Status

Status

Blaaskanker

Atezolizumab

Status

Lymfeklierkanker

Obinutuzumab

Status

Borstkanker

Atezolizumab

Status

Status

Pertuzumab

Status

Maagkanker

Pertuzumab

Status

Navragen bij deskundigen

Max Meijer

Ter beoordeling

Wijzigingsverzoeken

Nieuwe geneesmiddelen

Service

About this site